共 50 条
Blastic Plasmacytoid Dendritic Cell Neoplasm in Children
被引:17
|作者:
Li, Yixian
[1
]
Sun, Victoria
[2
]
Sun, Weili
[2
,3
]
Pawlowska, Anna
[2
]
机构:
[1] Childrens Hosp Montefiore, Pediat Hematol Oncol Marrow & Blood Cell Transpla, 3411 Wayne Ave,9th Floor, Bronx, NY 10467 USA
[2] City Hope Natl Med Ctr, Pediat Hematol Oncol & Hematopoiet Stem Cell Tran, 1500 East Duarte Rd, Duarte, CA 91010 USA
[3] Janssen Pharmaceut, 10990 Wilshire Blvd,Suite 300, Los Angeles, CA 90024 USA
关键词:
Pediatric blastic plasmacytoid dendritic cell neoplasm;
CD123;
CD4;
leukemia;
Stem cell transplant;
Tagraxofusp;
ACUTE-LEUKEMIA;
C-MYB;
IDENTIFICATION;
SENSITIVITY;
INVOLVEMENT;
TAGRAXOFUSP;
CHILDHOOD;
LYMPHOMA;
FEATURES;
RECEPTOR;
D O I:
10.1016/j.hoc.2020.01.008
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematological malignancy, derived from plasmacytoid dendritic cells. It mainly occurs in older adults, but has been reported across all age groups. Most patients present with skin lesions with or without marrow involvement and leukemic dissemination. Treatment with high-risk acute lymphoblastic leukemia therapy regimens with central nervous system prophylaxis is recommended in pediatric patients. Stem cell transplant in children is recommended for relapsed/refractory disease or high-risk disease at presentation. New targeted therapies including the recently FDA-approved anti-CD123 cytotoxin show great promise in improving the response rate.
引用
收藏
页码:601 / +
页数:13
相关论文